Gene therapy for hemophilias: the end of phenotypic testing or the start of a new era?

Abstract excerpt

: Hemophilia comprises two distinct genetic disorders caused by missing or defective clotting factor VIII (hemophilia A) or clotting factor IX (hemophilia B). The management of these conditions has been for long based on replacement therapies, but emerging evidence garnered from recent landmark studies suggests that a promising avenue toward routine use of gene therapy is clearly progressing forward, thus...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetic Therapy
• Share to Hemophilia A
• Share to Phenotype